lomustine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 96 Diseases   29 Trials   29 Trials   1185 News 


«12345678910111213...1516»
  • ||||||||||  Trial completion date, Trial primary completion date:  GBM AGILE: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (clinicaltrials.gov) -  Jun 30, 2022   
    P2/3,  N=1030, Recruiting, 
    N=38 --> 98 | Trial completion date: Mar 2022 --> Aug 2025 | Trial primary completion date: Mar 2022 --> Jul 2025 Trial completion date: Jun 2024 --> Jun 2028 | Trial primary completion date: Dec 2023 --> Jun 2026
  • ||||||||||  Amplimexon (imexon) / Amplimed Corp, SG 2000 / AstraZeneca
    Biomarker, Journal, Tumor Mutational Burden, IO biomarker, Pan tumor:  A pan-cancer analysis identifies HDAC11 as an immunological and prognostic biomarker. (Pubmed Central) -  Jun 8, 2022   
    HDAC11 is also associated with hallmark pathways, including epithelial mesenchymal transition, IL-6/JAK/STAT3, and allograft rejection pathways. Overall, we provide clues regarding the key role of HDAC11 in multiple cancers.
  • ||||||||||  lomustine / Generic mfg.
    Journal:  Lung toxicity of lomustine in the treatment of progressive gliomas. (Pubmed Central) -  Jun 8, 2022   
    Our findings support to limit lung function analyses on CCNU to patients with gliomas and pulmonary risk factors. However, all patients should be closely followed for clinical symptoms of pulmonary restriction.
  • ||||||||||  Matulane (procarbazine hydrochloride) / Leadiant Biosci
    Review, Journal:  Therapeutic Options in Neuro-Oncology. (Pubmed Central) -  Jun 5, 2022   
    The relevance of the immune system in carcinogenesis has led to the development of immunotherapy, through vaccination, blocking of immune checkpoints, oncolytic viruses, and adoptive immunotherapy using chimeric antigen receptor T cells. In this article we provide a comprehensive review of the signaling pathways underlying malignant transformation, the therapies currently used in the treatment of malignant gliomas and further explore therapies under development, including several ongoing clinical trials.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer (clinicaltrials.gov) -  May 25, 2022   
    P1,  N=90, Recruiting, 
    In this article we provide a comprehensive review of the signaling pathways underlying malignant transformation, the therapies currently used in the treatment of malignant gliomas and further explore therapies under development, including several ongoing clinical trials. Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
  • ||||||||||  Odomzo (sonidegib) / Sun Pharma
    Trial completion date, Trial primary completion date:  PersoMed-I: Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (clinicaltrials.gov) -  May 5, 2022   
    P2,  N=205, Not yet recruiting, 
    The worst OS in patients received LEAM can be explained by the fact that the regimen was used in our hospital earlier than others, when such drugs as Nivolumab and Brentuximab vedotin were not available to the patients with relapse after HDCT and ASCT. Trial completion date: Dec 2028 --> Mar 2030 | Trial primary completion date: Dec 2028 --> Mar 2030
  • ||||||||||  Avastin (bevacizumab) / Roche
    Dose-dependent efficacy of bevacizumab in recurrent glioblastoma. () -  Apr 28, 2022 - Abstract #ASCO2022ASCO_4490;    
    In this study we demonstrate that a reduced dose of bev (5 mg every 2-3 weeks) prolonged both the OS and PFS compared to a standard dose of 10 mg/kg every 2 weeks. This may represent a better and more cost-effective option for patients with rGBM in need of salvage therapy.
  • ||||||||||  berubicin (RTA 744) / CNS Pharma, WPD Pharma
    Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy. (Available On Demand; 416a) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_4438;    
    P2
    Background: Berubicin (also known as WP744) is a patented doxorubicin (Dox) analog with evidence that it crosses the BBB and has significant central nervous system (CNS) uptake...In models of intracranial orthotopic gliomas, Berubicin prolonged survival when compared to temozolomide, currently a standard of care in GBM...(“CNSP”) has licensed Berubicin and initiated a randomized, controlled clinical trial of Berubicin vs. Lomustine in adults with recurrent GBM after first line therapy...Patients will be stratified on the basis of MGMT methylation, there will be documentation of IDH WT status, and no prior administration of bevacizumab will be allowed...Additional studies in malignant diseases of the CNS (e.g., pediatric brain tumors, primary CNS lymphoma, metastatic tumors) are also being explored based on the potential for anthracycline activity in these indications. For the present study posted on clinicaltrials.gov as, additional details and contact information is available.
  • ||||||||||  Avastin (bevacizumab) / Roche, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
    Digital monitoring and assessments in patients with glioblastoma. (Available On Demand; 383) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_4400;    
    P1/2
    This is the first demonstration of digital measurement feasibility in a longitudinal study of pts with GBM. Digital measurements for pts with GBM could provide information on the impact of SEL-based treatment and functional outcomes in clinical trials and increase communication between clinicians and pts, thereby improving QoL and care management.
  • ||||||||||  Journal, HEOR:  Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols. (Pubmed Central) -  Apr 19, 2022   
    When diverse factors including chemotherapy treatment type (single-agent vs. multidrug regimens) and the onset and kind of adverse effects were considered, no significant variations in owners' perceptions of their pets' QoL were discovered. Chemotherapy type (single-agent vs. multidrug protocol) and related adverse events are shown, which did not influence owners' perception of their pet's QoL.Future prospective studies should look into clinical characteristics that might affect QoL, such as the patient's age, tumor stage, and protocol purpose (curative vs. palliative).
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed, Trial completion date, Trial primary completion date:  International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma (clinicaltrials.gov) -  Apr 19, 2022   
    P2/3,  N=360, Active, not recruiting, 
    Chemotherapy type (single-agent vs. multidrug protocol) and related adverse events are shown, which did not influence owners' perception of their pet's QoL.Future prospective studies should look into clinical characteristics that might affect QoL, such as the patient's age, tumor stage, and protocol purpose (curative vs. palliative). Recruiting --> Active, not recruiting | Trial completion date: Apr 2024 --> Dec 2026 | Trial primary completion date: Apr 2024 --> Dec 2026
  • ||||||||||  Avastin (bevacizumab) / Roche, NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI (clinicaltrials.gov) -  Apr 8, 2022   
    P=N/A,  N=30, Completed, 
    9-ING-41 plus/minus lomustine is safe and warrants further study in glioma patients. Recruiting --> Completed | N=85 --> 30 | Trial completion date: Aug 2022 --> Jan 2022 | Trial primary completion date: Aug 2021 --> Jan 2022
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Trial completion date:  REGOMA: Regorafenib in Relapsed Glioblastoma (clinicaltrials.gov) -  Apr 1, 2022   
    P2,  N=119, Active, not recruiting, 
    Our results demonstrated that histopathological subtype and several clinical variables were found to influence the prognosis of dogs with CTCL. Trial completion date: Oct 2021 --> Jun 2022
  • ||||||||||  NMS-293 / EMD Serono
    Enrollment open, Trial completion date, Trial primary completion date:  Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma (clinicaltrials.gov) -  Mar 27, 2022   
    P1/2,  N=125, Recruiting, 
    LOPP chemotherapy can be considered as a first-line treatment protocol against naïve hypercalcaemic non-indolent TCL. Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Nov 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Review, Journal:  Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges. (Pubmed Central) -  Mar 23, 2022   
    However, route of administration, size, pharmacokinetic properties, immune clearance and so on hamper nanomedicines' clinical uses. This review focuses on the benefits, avenues and challenges of nanoparticle-based drug-delivery systems for lung cancer treatment.